PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 09/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. EGRX, LTRN, LVTX, SONN, GBIO, JSPR, ESLA, PLUR, XLO, and XFORShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Eagle Pharmaceuticals (EGRX), Lantern Pharma (LTRN), LAVA Therapeutics (LVTX), Sonnet BioTherapeutics (SONN), Generation Bio (GBIO), Jasper Therapeutics (JSPR), Estrella Immunopharma (ESLA), Pluri (PLUR), Xilio Therapeutics (XLO), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Its Competitors Eagle Pharmaceuticals Lantern Pharma LAVA Therapeutics Sonnet BioTherapeutics Generation Bio Jasper Therapeutics Estrella Immunopharma Pluri Xilio Therapeutics X4 Pharmaceuticals Eagle Pharmaceuticals (NASDAQ:EGRX) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership. Which has more risk & volatility, EGRX or PHXM? Eagle Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Do insiders and institutionals believe in EGRX or PHXM? 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable earnings and valuation, EGRX or PHXM? Eagle Pharmaceuticals has higher revenue and earnings than PHAXIAM Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEagle Pharmaceuticals$257.55M0.16$35.64MN/AN/APHAXIAM TherapeuticsN/AN/A-$240KN/AN/A Is EGRX or PHXM more profitable? Company Net Margins Return on Equity Return on Assets Eagle PharmaceuticalsN/A N/A N/A PHAXIAM Therapeutics N/A N/A N/A Does the media refer more to EGRX or PHXM? In the previous week, Eagle Pharmaceuticals' average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score. Company Overall Sentiment Eagle Pharmaceuticals Neutral PHAXIAM Therapeutics Neutral SummaryEagle Pharmaceuticals beats PHAXIAM Therapeutics on 4 of the 5 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$153.68M$5.84B$10.14BDividend YieldN/A3.78%5.68%4.60%P/E RatioN/A41.0875.4125.98Price / SalesN/A4,942.15515.86180.60Price / CashN/A13.1937.5660.44Price / Book0.39103.7512.156.29Net Income-$240K-$90.99M$3.29B$271.07M7 Day PerformanceN/A2.86%0.74%3.87%1 Month PerformanceN/A21.20%5.00%5.49%1 Year PerformanceN/A526.77%62.55%25.86% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049EGRXEagle PharmaceuticalsN/A$3.21+0.3%N/A-25.5%$41.69M$257.55M0.00100Gap DownLTRNLantern Pharma2.3706 of 5 stars$3.83-2.5%$25.00+552.7%-4.7%$41.36MN/A-2.1520LVTXLAVA Therapeutics1.6594 of 5 stars$1.55+0.3%$2.69+73.8%-9.9%$40.65M$11.98M-1.4760Short Interest ↑SONNSonnet BioTherapeutics2.8721 of 5 stars$5.90+49.0%$20.00+239.0%-9.0%$40.30M$20K0.0010Positive NewsGap UpHigh Trading VolumeGBIOGeneration Bio4.0308 of 5 stars$5.93-1.3%$10.67+79.9%-77.2%$39.97M$19.89M-0.55150Positive NewsShort Interest ↓JSPRJasper Therapeutics3.4559 of 5 stars$2.43-5.1%$28.75+1,083.1%-89.3%$39.49MN/A-0.4020ESLAEstrella Immunopharma2.4986 of 5 stars$1.06+1.9%$16.00+1,409.4%-2.8%$39.29MN/A-4.08N/AGap UpPLURPluri2.7149 of 5 stars$4.94-3.9%$12.00+142.9%-7.7%$38.88M$330K-0.89150News CoverageUpcoming EarningsGap DownXLOXilio Therapeutics2.7706 of 5 stars$0.74+0.9%$3.00+307.3%-10.2%$38.18M$6.34M-0.9770XFORX4 Pharmaceuticals4.6422 of 5 stars$3.26-1.2%$34.17+948.1%-84.7%$37.20M$2.56M-0.2280Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Eagle Pharmaceuticals Competitors Lantern Pharma Competitors LAVA Therapeutics Competitors Sonnet BioTherapeutics Competitors Generation Bio Competitors Jasper Therapeutics Competitors Estrella Immunopharma Competitors Pluri Competitors Xilio Therapeutics Competitors X4 Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
